Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of $192.05 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 revenue of $815-845 million, versus the consensus of $868.12 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.